ADMS News and Press, Adamas Pharmaceuticals Inc. From 10/25/19

Noteworthy events during the week of October 27 - November 2 for healthcare investors. More news on: AMAG Pharmaceuticals, Inc., Agile Therapeutics, Inc., Adamas Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...

Gainers:  Teekay Offshore Partners L.P. (NYSE: TOO ) +32% . BioCardia ( OTCQB:BCDA ) +25% . Roan Resources (NYSE: ROAN ) +21% . Conformis (NASDAQ: CFMS ) +18% . Constellation Pharmaceuticals (NASDAQ: CNST ) +15% . Pintec Technology Holdings (NASDAQ: PT ) +13% . Geron Corporation...

Gainers:  Dova Pharmaceuticals (NASDAQ: DOVA ) +38% . USA Technologies ( OTC:USAT ) +28% . Farmmi (NASDAQ: FAMI ) +24% . Thor Industries (NYSE: THO ) +21% . GTT Communications (NYSE: GTT ) +15% . Patrick Industries (NASDAQ: PATK ) +12% . Seattle Genetics (NASDAQ: SGEN ) +10% . ...

EMERYVILLE, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane, the Company’s Chief Executiv...

EMERYVILLE, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, announced today the presentation of new data on GOCOVRI ® (aman...

Bellus Health ( BLUSF ) could have its shares soon trading on the NASDAQ exchange. This is a very favourable announcement. As a result, we believe that market liquidity will increase, which may push the share price of Bellus up. We are positive on the stock. Another stock catalyst, which may e...

Adamas Pharmaceuticals (NASDAQ: ADMS ) appoints  Neil McFarlane as CEO and the member of Board of Directors, effective September 16, 2019. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

- Gregory Went, Ph.D., Founder, transitions to a strategic advisory role - David Mahoney, lead independent director, appointed to Chairman of the Board EMERYVILLE, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceuti...

Adamas Pharmaceuticals (NASDAQ: ADMS ) initiated with Neutral rating and $8 (50% upside) price target at Cantor Fitzgerald. More news on: Adamas Pharmaceuticals, Inc., Covetrus, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...

Mitsubishi Tanabe Pharma America ( OTCPK:MTZPY -1.5% ) initiates a Phase 3 clinical trial, BouNDless , evaluating continuous subcutaneously administered carbidopa/levodopa (ND0612) compared to the oral formulation in Parkinson's disease (PD) patients. More news on: Mitsubishi Tanabe P...